Correction to: Leukemia 10.1038/s41375-020-01042-y
Table 3 of the original article was not correct. The corrected version can be found below:
Table 3.
SMR and OS after achieving or failure of PFS at selected time points.
| 3 years from time point | 5 years from time point | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| SMR | Actual 3-y OSa | Expected | Actual 5-y OSa | Expected | |||||
| PFS time point | No. of Patients | (95% CI) | Pb | No. of Patients | % (95% CI) | 3-y OS (%) | No. of Patients | % (95% CI) | 5-y OS (%) |
| Patients achieved PFS | |||||||||
| All stage (I-IV) | |||||||||
| 12 months | 1274 | 3.1 (2.6–3.7) | <0.001 | 594 | 88.8 (86.9–90.8) | 96.9 | 195 | 86.5 (84.1–88.9) | 94.4 |
| 24 months | 1014 | 1.8 (1.3–2.3) | <0.001 | 380 | 94.8 (93.2–96.4) | 96.9 | 100 | 92.2 (89.6–94.9) | 94.3 |
| 36 months | 793 | 1.0 (0.6–1.6) | 0.953 | 188 | 97.0 (95.2–98.8) | 97.0 | 32 | 93.0 (88.7 –97.5) | 94.7 |
| Stage I-II | |||||||||
| 12 months | 1169 | 2.7 (2.3–3.3) | <0.001 | 573 | 90.2 88.3–92.1) | 96.9 | 190 | 87.8 (85.4–90.2) | 94.4 |
| 24 months | 950 | 1.5 (1.1–2.0) | 0.009 | 366 | 95.5 (94.0–97.1) | 96.9 | 100 | 92.9 (90.2–95.6) | 94.3 |
| 36 months | 752 | 1.0 (0.6–1.6) | 0.929 | 183 | 97.0 (95.2–98.8) | 97.0 | 32 | 93.0 (88.7–97.6) | 94.6 |
| Stage III-IV | |||||||||
| 12 months | 105 | 11.4 (7.5–17.4) | <0.001 | 21 | 69.7 (59.4–81.7) | 97.3 | 5 | 69.7 (59.4–81.7) | 95.4 |
| 24 months | 64 | 9.6 (5.0–18.4) | <0.001 | 14 | 83.1 (73.4–94.2) | 97.5 | – | – | – |
| 36 months | 41 | 2.5 (0.4–18.0) | 0.352 | 5 | 96.4 (89.8–100) | 97.7 | – | – | – |
| Patients with progression | |||||||||
| All stage (I-IV) | |||||||||
| 12 months | 246 | 65.8 (56.8–76.2) | <0.001 | 27 | 22.9 (17.9–29.5) | 96.4 | 8 | 17.1 (11.6–25.2) | 94.8 |
| 24 months | 348 | 71.4 (62.9–81.1) | <0.001 | 40 | 24.3 (19.8–30.0) | 97.1 | 14 | 19.2 (14.3–25.9) | 95.8 |
| 36 months | 388 | 55.0 (48.7–62.0) | <0.001 | 41 | 25.4 (20.9–30.8) | 96.4 | 14 | 20.3 (15.3–26.8) | 93.2 |
| Stage I-II | |||||||||
| 12 months | 201 | 62.7 (53.3–73.7) | <0.001 | 25 | 23.9 (18.4–31.1) | 96.3 | 7 | 17.4 (11.5–26.4) | 94.6 |
| 24 months | 289 | 67.3 (58.5–77.2) | <0.001 | 37 | 25.8 (20.9–32.0) | 97.0 | 13 | 20.1 (14.7–27.4) | 95.6 |
| 36 months | 325 | 50.4 (44.2–57.6) | <0.001 | 38 | 26.9 (22.1–32.9) | 96.3 | 13 | 21.2 (15.9–28.4) | 92.8 |
| Stage III-IV | |||||||||
| 12 months | 45 | 85.9 (60.4–122.2) | <0.001 | 2 | 14.5 (5.6–37.4) | 97.4 | – | – | – |
| 24 months | 59 | 103.6 (76.0–141.3) | <0.001 | 3 | 13.7 (5.9–31.8) | 97.9 | – | – | – |
| 36 months | 63 | 103.4 (76.4–140.0) | <0.001 | 3 | 13.8 (6.0 –31.9) | 97.9 | – | – | – |
SMR standardized mortality ratio, OS overall survival, PFS progression-free survival.
aActual 3- or 5-year OS was defined as subsequent OS of patients who achieved or failed to achieve PFS at 12, 24 or 36 months after initial treatment based on patients with ENKTCL vs. expected 3- or 5-year OS based on age-, sex- and country-matched general population data.
bCompared with the age- and sex-matched general Chinese population.
Contributor Information
Shu-Nan Qi, Email: medata@163.com.
Ye-Xiong Li, Email: yexiong12@163.com.